Effect of Drug Resistance on the Generation of Secondary Cases of Tuberculosis

Journal of Infectious Diseases

Volumn 188, Issue 12, 2003, Pages 1878-1884

  Burgos, Marcos ^a,b,c   DeRiemer, Kathryn ^a   Small, Peter M ^a   Hopewell, Philip C ^b   Daley, Charles L ^b  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ETHAMBUTOL; ISONIAZID; PYRAZINAMIDE; RIFAMPICIN; STREPTOMYCIN;

ARTICLE; CALCULATION; CONFIDENCE INTERVAL; CONTROLLED STUDY; DRUG SENSITIVITY; GENOTYPE; HUMAN; INCIDENCE; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MULTIDRUG RESISTANCE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PATHOGENICITY; PRIORITY JOURNAL; UNITED STATES;

ANTI-BACTERIAL AGENTS; ANTIBIOTICS, ANTITUBERCULAR; ANTITUBERCULAR AGENTS; CONFIDENCE INTERVALS; DNA TRANSPOSABLE ELEMENTS; DRUG RESISTANCE, BACTERIAL; HUMANS; INCIDENCE; ISONIAZID; MYCOBACTERIUM TUBERCULOSIS; RIFAMPIN; SAN FRANCISCO; STREPTOMYCIN; TUBERCULOSIS;

EID: 0347319567     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/379895     Document Type: Article

References (28)

1. Farmer P. The major infectious diseases in the world - to treat or not to treat? N Engl J Med 2001; 345:208-10.
2. Gupta R, Kim JY, Espinal MA, et al. Responding to market failures in tuberculosis control. Science 2001; 293:1049-51.
3. Espinal MA, Laszlo A, Simonsen L, et al. Global trends in resistance to antituberculosis drugs. World Health Organization/International Union Against Tuberculosis and Lung Disease Working Group on Anti-Tuberculosis Drug Resistance Surveillance. N Engl J Med 2001; 344:1294-303.
4. Pablos-Mendez A, Raviglione MC, Laszlo A, et al. Global surveillance for antituberculosis-drug resistance, 1994-1997. World Health Organization/ International Union Against Tuberculosis and Lung Disease Working Group on Anti-Tuberculosis Drug Resistance Surveillance. N Engl J Med 1998; 338:1641-9.
5. Bjorkman J, Hughes D, Andersson DI. Virulence of antibiotic-resistant Salmonella typhimurium. Proc Natl Acad Sci USA 1998; 95:3949-53.
6. Andersson DI, Levin BR. The biological cost of antibiotic resistance. Curr Opin Microbiol 1999; 2:489-93.
7. Bjorkman J, Nagaev I, Berg OG, Hughes D, Andersson DI. Effects of environment on compensatory mutations to ameliorate costs of antibiotic resistance. Science 2000; 287:1479-82.
8. Dye C, Williams BG, Espinal MA, Raviglione MC. Erasing the world's slow stain: strategies to beat multidrug-resistant tuberculosis. Science 2002; 295:2042-6.
9. Snider DE Jr, Kelly GD, Cauthen GM, Thompson NJ, Kilburn JO. Infection and disease among contacts of tuberculosis cases with drug-resistant and drug-susceptible bacilli. Am Rev Respir Dis 1985; 132:125-32.
10. Middlebrook G. Isoniazid resistance and catalase activity of the tubercle bacilli. Am Rev Tuberc 1954; 69:471-2.
11. Cohn M, Kovitz C, Oda U. Studies on isoniazid and tubercle bacilli: the growth requirements, catalase activities, and pathogenic properties of isoniazid resistant mutants. Am Rev Tuberc 1954; 70:641-64.
12. Riley RL, Mills CC, O'Grady F, Sultan LU, Wittstandt F, Shivpuri DN. Infectiousness of air from a tuberculosis ward: comparative infectiousness of different patients. Am Rev Respir Dis 1962; 85:511-25.
13. van Soolingen D, Borgdorff MW, de Haas PE, et al. Molecular epidemiology of tuberculosis in the Netherlands: a nationwide study from 1993 through 1997. J Infect Dis 1999; 180:726-36.
14. Godfrey-Faussett P, Sonnenberg P, Shearer SC, et al. Tuberculosis control and molecular epidemiology in a South African gold-mining community. Lancet 2000; 356:1066-71.
15. Garcia-Garcia ML, Ponce de Leon A, Jimenez-Corona ME, et al. Clinical consequences and transmissibility of drug-resistant tuberculosis in southern Mexico. Arch Intern Med 2000; 160:630-6.
16. Jasmer RM, Hahn JA, Small PM, et al. A molecular epidemiologic analysis of tuberculosis trends in San Francisco, 1991-1997. Ann Intern Med 1999; 130:971-8.
17. Chin DP, DeRiemer K, Small PM, et al. Differences in contributing factors to tuberculosis incidence in U.S.-born and foreign-born persons. Am J Respir Grit Care Med 1998; 158:1797-803.
18. Kent PT, Kubica GP. Public health mycobacteriology: a guide for the level III laboratory. Atlanta: Centers for Disease Control and Prevention, 1985.
19. Siddiqi S. Radiometric (BACTEC) tests for slowly growing mycobacteria. In: Isenberg HD, ed. Clinical microbiology procedures handbook. Washington, DC: American Society for Microbiology Press, 1992:11-25.
20. van Embden JD, Cave MD, Crawford JT, et al. Strain identification of Mycobacterium tuberculosis by DNA fingerprinting: recommendations for a standardized methodology. J Clin Microbiol 1993; 31:406-9.
21. Royston P. Estimating departure from normality. Stat Med 1991; 10: 1283-93.
22. Rosner B. Fundamentals of Biostatistics. 5th ed. Pacific Grove, CA: Duxbury Thomson Learning, 2000.
23. Glantz S. Primer of biostatistics. 4th ed. New York: McGraw-Hill, 1997: 89-90, 350-3.
24. Behr MA, Warren SA, Salamon H, et al. Transmission of Mycobacterium tuberculosis from patients smear-negative for acid-fast bacilli. Lancet 1999; 353:444-9.
25. Li Z, Kelley C, Collins F, Rouse D, Morris S. Expression of katG in Mycobacterium tuberculosis is associated with its growth and persistence in mice and guinea pigs. J Infect Dis 1998; 177:1030-5.
26. Pym AS, Domenech P, Honore N, Song J, Deretic V, Cole ST. Regulation of catalase-peroxidase (KatG) expression, isoniazid sensitivity and virulence by furA of Mycobacterium tuberculosis. Mol Microbiol 2001; 40:879-89.
27. Bradford WZ, Martin JN, Reingold AL, Schecter GF, Hopewell PC, Small PM. The changing epidemiology of acquired drug-resistant tuberculosis in San Francisco, USA. Lancet 1996; 348:928-31.
28. Cohen T, Sommers B, Murray M. The effect of drug resistance on the fitness of Mycobacterium tuberculosis. Lancet Infect Dis 2003; 3:13-21.